Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Olema Pharmaceuticals ( (OLMA) ) has issued an announcement.
On January 30, 2026, Olema Pharmaceuticals, Inc. announced that Chief Operating and Financial Officer Shane Kovacs departed the company on that date to pursue new opportunities, though he will remain as a consultant through August 1, 2026 under a separation and consulting agreement. Under the agreement, Kovacs will continue to vest in his existing equity awards during the consulting period and receive a lump-sum payment totaling $621,283, while Olema launches a search for a new Chief Financial Officer and Chief Executive Officer Sean Bohen assumes the role of principal financial officer on an interim basis, with the company emphasizing that Kovacs’ departure did not arise from any disagreement over financial operations, policies, or practices.
The most recent analyst rating on (OLMA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn), partly offset by strong technical trends (price well above longer-term averages with positive MACD) and favorable recent clinical/program updates. Valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Average Trading Volume: 3,775,048
Technical Sentiment Signal: Buy
Current Market Cap: $1.93B
See more insights into OLMA stock on TipRanks’ Stock Analysis page.